Story
Quest Diagnostics Stock Slides on Proposed Medicare Reimbursement Cuts
Summary
Shares of Quest Diagnostics fell over 5% in after-hours trading following a proposal from the Centers for Medicare & Medicaid Services to reduce reimbursement rates for laboratory tests by up to 15% starting in 2027.
Quest Diagnostics (NYSE:DGX) shares fell sharply in after-hours trading after federal regulators proposed significant cuts to Medicare reimbursement rates for laboratory services, threatening a key revenue stream for the company and its competitors.
Proposed Rate Cuts Trigger Sell-Off
The stock dropped 5.2% to $232.12 in after-hours trading on Thursday, according to the source. The decline followed a preliminary announcement from the Centers for Medicare & Medicaid Services (CMS) that could reduce payments under the Clinical Laboratory Fee Schedule by up to 15% beginning January 1, 2027.
CMS stated the proposed realignment is based on data from over 6,400 laboratories, which suggested Medicare has been overpaying for these services by approximately 16% compared to private insurers. The agency estimates the change would save taxpayers around $1 billion per year.
Market Impact and Context
The proposed cuts represent a significant headwind for the entire diagnostics sector. Labcorp (NYSE:LH), Quest's primary competitor, also faced the same regulatory pressure, confirming a sector-wide reaction. The sell-off was particularly sharp as it came just hours after Quest's stock had reached a new 52-week high of $248.84 during regular trading.
AdThe after-hours decline erased the day's gains and pushed the stock significantly lower, highlighting the material risk investors see in the proposal. Broader market indices were largely flat, underscoring that the drop was driven by the specific regulatory news rather than a wider economic shift.
Path to Finalization
The proposed rates are not yet final. According to the CMS announcement, laboratories and industry groups will have approximately 30 days to submit formal comments on the preliminary schedule.
CMS is expected to release the final fee schedule for calendar year 2027 in November 2026. This timeline suggests a period of uncertainty is likely to weigh on the stocks of Quest and its peers in the near term.
Read next
More on Stocks
Tomi Environmental Stock Jumps 15% After Terminating Merger with Carbonium Core
Shares of Tomi Environmental Solutions (NASDAQ:TOMZ) surged in after-hours trading after the company and Carbonium Core Inc. mutually agreed to cancel their planned merger. Management expressed confidence in the company's standalone growth prospects.
Vicor Stock Surges After Doubling Q3 Revenue Growth Forecast on Patent Royalties
The power systems company more than doubled its sequential revenue growth forecast for the third quarter, citing new royalty income from its patented technology used in AI data centers.
Endava Shares Drop 10% After CFO Placed on Leave Amid Accounting Investigation
The technology services provider announced CFO Mark Thurston was placed on administrative leave pending an investigation into the accounting treatment of certain customer and supplier agreements.
MOEX Russia Index Slips 0.78% as Mining and Energy Stocks Decline
The Russian stock market closed lower on Monday, with the benchmark MOEX Index falling 0.78% due to widespread losses in the mining, oil and gas, and manufacturing sectors. The decline came as crude oil prices fell, while the Russian ruble remained stable.